Zevra Therapeutics (ZVRA) director files report showing no holdings

Rhea-AI Filing Summary

Zevra Therapeutics, Inc. director Alicia Secor has filed an initial insider ownership report indicating that she does not beneficially own any of the company’s securities. The filing is made as a Form filed by one reporting person in her capacity as a director of Zevra Therapeutics.

The event date for this disclosure is 12/02/2025, and the form is signed by an attorney-in-fact on her behalf. The remarks section explicitly states that no securities are beneficially owned, meaning there are currently no reported direct or indirect holdings by this director.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Secor Alicia

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

1180 CELEBRATION BOULEVARD, SUITE 103

(Street)

CELEBRATION FL 34747

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/02/2025

3. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Alicia Secor	12/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does this insider filing reveal about Zevra Therapeutics (ZVRA)?

The filing shows that director Alicia Secor currently reports no beneficial ownership of Zevra Therapeutics, Inc. securities as of the reported event date.

Who is the reporting person in this Zevra Therapeutics insider report?

The reporting person is Alicia Secor, identified in the signature block, and her relationship to Zevra Therapeutics, Inc. is marked as a Director.

What is the relationship of the reporting person to Zevra Therapeutics (ZVRA)?

The reporting person is a Director of Zevra Therapeutics, Inc., as indicated by the checked box for Director in the relationship section of the report.

Does the director report owning any Zevra Therapeutics shares or derivatives?

No. The remarks explicitly state that no securities are beneficially owned, and the tables for non-derivative and derivative securities show no reported holdings.

What is the event date associated with this Zevra Therapeutics insider disclosure?

The Date of Event Requiring Statement is listed as 12/02/2025, which is the effective date for the ownership status reported.

Who signed the filing for the reporting person in this ZVRA insider report?

The address listed is c/o Zevra Therapeutics, Inc., 1180 Celebration Boulevard, Suite 103, which is used for the reporting person’s correspondence.